CXCL3 is an ELR CXC chemokine, structurally and functionally related to GRO1 (CXCL1), GRO2 (CXCL2), and interleukin-8 (CXCL8). CXCL3 binds to the CXCR2 receptor; this receptor is shared with other ELR CXC chemokines (CXCL1, CXCL2, CXCL5, CXCL6, CXCL7, and CXCL8). CXC chemokines play a crucial role in the first phase of inflammation; in this stage, PMN cells are rapidly chemoattracted. In the next step of inflammation, the CC chemokines (MCPs) attract different cell subpopulations such as T cells, monocytes, basophils, and eosinophils. MMP12, mainly produced by macrophages, modulates the activity of ELR-CXC chemokines, and it cleavages human CXCL1, CXCL2 and CXCL3 within the ELR sequence at Glu6-Leu7. The ELR sequence is critical in receptor binding; therefore, the cleavage inactivates these chemokines and abrogates the PMN influx. CXCL3 is expressed in colon carcinoma, and it is associated with metastasis.? Also, CXCL1, CXCL2 and CXCL3 have been showed to be highly expressed in patients with malignant melanoma. CXCL3, in addition to other chemokines, is induced by IL-17A in psoriasis.
Size
10 μg
Concentration
n/a
Applications
BA
Other Names
Gro3, Groγ, Small inducible cytokine subfamily B, member 3 (Scyb3), macrophage inflammatory protein-2 beta (MIP2B), CINC-2b